The Four Pillars of Heart Failure Therapy: Starting All Four at Once

There is no substantial long-term beneficial role — it is like flogging a dead horse, a transient cardiac output boost without sustained benefit. It's useful only as a short-term emergency bridge for a profoundly hypotensive patient. We now more routinely use noradrenaline rather than dobutamine in acute low-output heart failure.

The Sgarbossa criteria identify acute myocardial infarction in the presence of a left bundle branch block, where it is otherwise difficult to tell whether ECG changes represent an acute MI or simply the LBBB pattern — specifically, 4mm or more of ST elevation discordant to the QRS is considered an acute MI regardless of the LBBB. This is used specifically in the context of chest pain with LBBB, not in the context of established heart failure management.

A failing heart relies on two compensatory mechanisms: increased heart rate and elevated blood pressure. A beta blocker reduces both, so cardiac output falls initially and the patient feels rough — but only for the first one to two weeks. After that, sustained reduction in neurohormonal activation reverses adverse cardiac remodelling and the patient improves steadily. Always counsel patients about this dip in advance and reassure them it will get better; a heart failure nurse is an excellent resource for this kind of communication.

BNP and NT-proBNP are released in response to myocardial wall stress, so a normal BNP with a normal ECG makes acute heart failure very unlikely as the cause of a patient's breathlessness — the dyspnoea is most likely pulmonary or another non-cardiac cause. One nuance: in a patient presenting late, days after the onset of acute heart failure while partially compensating, BNP can occasionally read lower than expected, so very recent-onset context still matters.

This is congestive cardiac failure — combined right and left heart failure — and the patient should ideally be hospitalised for close monitoring of renal function and electrolytes. For NYHA class 3 or 4 patients like this, we now routinely add acetazolamide alongside loop diuretics, which improves diuresis and speeds resolution of congestion as long as renal function isn't severely impaired. If blood pressure is low, low-dose renal-dose dopamine in addition to diuretics can help significantly, particularly with right heart failure and valvular dysfunction. Given the liver cirrhosis, use a higher dose of spironolactone, since it also acts on hepatic ascites, and monitor hepatorenal function closely.

None of them, on its own. Current guidelines call for all four pillars together in any symptomatic patient with an ejection fraction below 40%, since each acts on a different mechanism and outcomes are demonstrably better with simultaneous up-titration than sequential dosing before discharge.

Bisoprolol, carvedilol and metoprolol succinate have trial evidence in heart failure. Atenolol and nebivolol have not been studied in this setting and shouldn't be substituted for them.

No. They relieve symptoms but carry no mortality benefit, and should never be used as the primary or sole treatment.

No. Giving a beta blocker to a heart failure patient was once considered dangerous. Within roughly a decade, the evidence reversed so completely that withholding one became the outlier practice.